2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Lymphoid
1
Gastrointestinal
1
Endocrine
1
CNS
1
Conditions
Neuroendocrine Tumors
6
Gastro-enteropancreatic neuroendocrine tumor
2
Rhabdomyosarcoma
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Lymphoma
1
Hyperinsulinism
1
Colorectal Neoplasms
1
Central Nervous System Neoplasms
1
Interventions
Vincristine
25
Cyclophosphamide
25
Irinotecan
21
Temozolomide
18
Doxorubicin
16
Radiotherapy
15
Filgrastim
15
Ifosfamide
14
Dactinomycin
14
Etoposide
11
Vinorelbine
9
Melphalan
9
Magnetic Resonance Spectroscopy
9
Granulocyte Colony-Stimulating Factor
9
Radiation
8
pegfilgrastim
7
X-Rays
7
Specimen Handling
7
Sirolimus
7
Topotecan
6
Phantoms, Imaging
6
Peripheral Blood Stem Cell Transplantation
6
Gemcitabine
6
cixutumumab
5
Busulfan
5
Biopsy
5
temsirolimus
4
irinotecan sucrosofate
4
fludarabine
4
etoposide phosphate
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Rhabdomyosarcoma
×
amino-acid, glucose, and electrolyte solution
×
Clear all
NCT06441331
2026-05-01
KinLET
ITM Solucin GmbH
Phase 1
Recruiting
20 enrolled